CLINICAL_TRIALS
trial_result
· 2011-09-15
Clinical Trial Update: A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer [Phase 1]
Summary
A dose-escalation Phase 1 trial of the IGF-1 receptor inhibitor AXL1717 in patients with advanced cancer has completed. The update reports safety data and early…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Axelar AB | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED